JonesResearch downgraded Clearside Biomedical (CLSD) to Hold from Buy without a price target after the company said it is exploring strategic alternatives to maximize shareholder value. The firm finds it unclear if this strategic review will result in a transaction. It cites Clearside’s “unclear path ahead” for the downgrade.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLSD:
- Hold Rating for Clearside Biomedical Amid Strategic Uncertainty and Financial Constraints
- Clearside Biomedical Explores Strategic Alternatives Amid Economic Challenges
- Clearside Biomedical transitions all employees to consulting roles
- Clearside Biomedical to explore strategic alternatives to advance SCS platform
- Clearside Biomedical Approves Share Increase at Annual Meeting